Antifungal News and Research

RSS

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

HDAC inhibitors may also be effective against kidney stones

Anyone who has suffered from kidney stones is keenly aware of the lack of drugs to treat the condition, which often causes excruciating pain.

15 Aug 2014

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose.

14 Aug 2014

Research hopes to protect hundreds of newborns from severe health problems by protein in milk

An international effort led by the University of Sydney hopes to protect hundreds of Bangladeshi newborns from a host of severe health problems by assessing the effect of lactoferrin, a natural protein found in breast and cow's milk, in the treatment of iron deficiency anemia in pregnancy.

13 Aug 2014

Antifungal drug resistance evoked through RNAi-dependent epimutations

Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs.

27 Jul 2014

Funding for antibiotic research in the UK are inadequate, study reveals

Less than 1% of research funding awarded by public and charitable bodies to UK researchers in 2008–13 was awarded for research on antibiotics, according to new research published in The Lancet Infectious Diseases.

25 Jul 2014

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients.

24 Jul 2014

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.

9 Jul 2014

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination.

9 Jul 2014

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.

30 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service.

28 Apr 2014

Scientists discover protein structure that helps common fungal pathogen to infect humans

A team that includes scientists from the School of Medicine at The University of Texas Health Science Center at San Antonio, Johns Hopkins University and St. Mary's University reported the structure of a protein that helps a common fungus to infect the body.

17 Apr 2014

New approach could lead to devising alternative tools for cancer therapy

Inducing biological tissue damage with an atmospheric pressure plasma source could open the door to many applications in medicine

26 Mar 2014

Honey helps fight antibiotic resistance, says study

Honey, that delectable condiment for breads and fruits, could be one sweet solution to the serious, ever-growing problem of bacterial resistance to antibiotics, researchers said here today.

17 Mar 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Researchers develop screening assay that quickly assesses nearly 1,500 compounds' effect on estrogen

A team of researchers at City of Hope has developed a screening assay that can quickly assess up to 1,536 compounds' effect on estrogen activity in the body. The test can also evaluate whether chemicals act as inhibitors of aromatase, an enzyme linked to breast cancer that converts androgen to estrogen.

20 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

Manchester researchers become first in world to assess all genetic links with fungal lung infection CPA

A grandfather-of-three from Tameside is helping University of Manchester researchers become the first in the world to assess all the genetic links with Chronic Pulmonary Aspergillosis (CPA) - a debilitating fungal lung infection that claims the lives of thousands of people in the UK and millions more worldwide.

From The University of Manchester 12 Feb 2014

Drug used for treating breast cancer also kills fungal disease

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more HIV/AIDS patients than tuberculosis, appear in mBio-, the online open-access journal of the American Society for Microbiology (ASM.)

11 Feb 2014